Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

Vesicular glutamate transporters (VGLUTs) were long thought to be specific markers of glutamatergic excitatory transmission. The discovery, two decades ago, of the atypical VGLUT3 has thoroughly modified this oversimplified view. VGLUT3 is strategically expressed in discrete populations of glutamatergic, cholinergic, serotonergic, and even GABAergic neurons. Recent reports show the subtle, but critical, implications of VGLUT3-dependent glutamate co-transmission and its roles in the regulation of diverse brain functions and dysfunctions. Progress in the neuropharmacology of VGLUT3 could lead to decisive breakthroughs in the treatment of Parkinson's disease (PD), addiction, eating disorders, anxiety, presbycusis, or pain. This review summarizes recent findings on VGLUT3 and its vesicular underpinnings as well as on possible ways to target this atypical transporter for future therapeutic strategies. Crown Copyright © 2021. Published by Elsevier Ltd. All rights reserved.

Citation

Mathieu Favier, Nicolas Pietrancosta, Salah El Mestikawy, Giuseppe Gangarossa. Leveraging VGLUT3 Functions to Untangle Brain Dysfunctions. Trends in pharmacological sciences. 2021 Jun;42(6):475-490

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 33775453

View Full Text